Choosing a course is one of the most important decisions you'll ever make! View our courses and see what our students and lecturers have to say about the courses you are interested in at the links below.
Each year more than 4,000 choose NUI Galway as their University of choice. Find out what life at NUI Galway is all about here.
About NUI Galway
About NUI Galway
Since 1845, NUI Galway has been sharing the highest quality teaching and research with Ireland and the world. Find out what makes our University so special – from our distinguished history to the latest news and campus developments.
Colleges & Schools
Colleges & Schools
NUI Galway has earned international recognition as a research-led university with a commitment to top quality teaching across a rang of key areas of expertise.
Business & Industry
Guiding Breakthrough Research at NUI Galway
We explore and facilitate commercial opportunities for the research community at NUI Galway, as well as facilitating industry partnership.
- Alumni, Friends & Supporters
At NUI Galway, we believe that the best learning takes place when you apply what you learn in a real world context. That's why many of our courses include work placements or community projects.
Dr Eva Szegezdi M.Sc., Ph.D.
Mechanism of signal transduction in order to understand the driving forces of disease progression and to identify targets for therapy.
Identified that the pro-inflammatory cytokines interleukin-1b and interferon g act in synergy to induce beta-cell death and thus contribute to type I diabetes. Induction of nitric oxide synthase is necessary and sufficient to cause pancreatic beta cell apoptosis. Current in vivo studies assess the potential of IFNg neutralization to revert the progression of type I diabetes and promote pancreas recovery.
The potential of adult MSCs to repair ischemic heart damage was studied. The contribution of the components of ischemic conditions (hypoxia, nutrient deprivation, oxygen deprivation, inhibition of glues metabolism) to loss of cardiac muscle contractility and cell death was determined. Found that MSCs well tolerate the conditions which are damaging to cardiomyocyte function and survival. MSCs are able to retain functionality during prolonged ischemia by surviving on glycolytic energy production. Active glycolysis on the other hand provides an essential survival factor in MSCs and inhibition of glycolysis triggers rapid MSC death.
Regulation of apoptotic pathways in cancer cells and to the engineering of death ligands (TNF family of cytokines) for selective death receptor activation or receptor neutralization.
First demonstration that high affinity, receptor-selective variants of the death ligand, TRAIL, generated by computational design are more efficient death receptors activators and inducers of tumour cell death than wild type TRAIL. Found that the apoptosis-inducing potency of TRAIL is limited by its promiscuity, i.e. its ability to bind to four receptors due to formation of inactive heteromeric receptor complexes and fast kinetics of receptor activation is a key element in induction of apoptosis. Identified point mutations in TRAIL that provide receptor selectivity and thus enhance anti-tumour efficacy.
Current studies aim to develop a so called ratiometric analysis of protein expression. The working hypothesis is that rather than the absolute amount of a given protein, its amount relative to other proteins playing a role in a given biological process (i.e. the expression ratio of proteins) determines the biological response of a cell to any given stimulus.
Project: Development of antagonistic cytokine variants for treatment of type I diabetes ( IFN)
Start/End Dates: 01-DEC-08 / 30-NOV-09
Project: Uncoupling of death receptor-induced nuclear factor kappa B activation from apoptosis ( CRF09SZE)
Start/End Dates: 01-DEC-09 / 30-NOV-12
Project: Novel ratiometric approach to identify decisive molecular interactions of the TRAIL apoptotic machinery ( 09/SIRG/B1575)
Start/End Dates: 01-OCT-09 / 30-SEP-13
|Vincenz, L; Szegezdi, E; Jäger, R; Holohan, C; O’Brien, T; Samali, A (2011) 'Cytokine-induced b-cell stress and death in type 1 diabetes mellitus' In: Type 1 Diabetes - Complications, Pathogenesis, and Alternative Treatments. Croatia: Intech. [Details]|
Peer Reviewed Journals
|O'Leary L, van der Sloot A, Serrano L, Reis C, Cool R, Quax WJ, Deegan S, Murillo L, Thompson K, de Sampaio P, Ryan AE, Singh Dhami SP, Murphy G, Szegezdi E (2015) 'Decoy receptors block TRAIL sensitivity at supra-cellular level: the role of stromal cells in controlling tumour TRAIL-sensitivity'. Oncogene, . [Details]|
|Zhou, J,Reidy, M,O'Reilly, C,Jarikote, DV,Negi, A,Samali, A,Szegezdi, E,Murphy, PV (2015) 'Decorated Macrocycles via Ring-Closing Double-Reductive Amination. Identification of an Apoptosis Inducer of Leukemic Cells That at Least Partially Antagonizes a 5-HT2 Receptor'. Organic Letters, 17 :1672-1675. [DOI] [Details]|
|Eimear O’ Reilly, Corrado Santocanale, Eva Szegezdi (2015) 'Molecular targets for novel drug development in pancreatic cancer'. Annals on Cancer Research, 2 (3). [Details]|
|Séverine Cruet-Hennequart; Tanja Paavilainen; Michael O’Dwyer; Réka Tóth; Michael P Carty; Afshin Samali; Eva Szegezdi (2015) 'G2/M Arrest Sensitises Erythroid Leukemia Cells to TRAIL-induced Apoptosis'. Journal of Leukemia, 4 . [DOI] [Details]|
|Paul O’Reilly, Csaba Ortutay, Grainne Gernon, Enda O’Connell, Cathal Seoighe, Susan Boyce, Luis Serrano, Eva Szegezdi (2014) 'Co-acting gene networks predict TRAIL responsiveness of tumour cells with high accuracy'. BMC Genomics, 15 . [DOI] [Details]|
|Denis V. Baev, Janusz Krawczyk, Michael O’Dwyer, Eva Szegezdi (2014) 'The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia Initiating cells'. Leukemia research, 3 :79-82. [Details]|
|van Dijk, M,Halpin-McCormick, A,Sessler, T,Samali, A,Szegezdi, E (2013) 'Resistance to TRAIL in non-transformed cells is due to multiple redundant pathways'. Cell Death & Disease, 4 . [DOI] [ARAN Link] [Details]|
|Leanza L, O' Reilly P, Doyle A, Venturini E, Zoratti M, Szegezdi E, Szabo I (2013) 'Correlation between potassium channel expression and sensitivity to drug-induced cell death in tumor cell lines'. Current pharmaceutical design, . [Details]|
|Sessler T, Healy S, Samali A, Szegezdi E (2013) 'Structural determinants of DISC function: New insights into death receptor-mediated apoptosis signalling'. Pharmacology & therapeutics, . [DOI] [Details]|
|Szegezdi, E,van der Sloot, AM,Mahalingam, D,O'Leary, L,Cool, RH,Munoz, IG,Montoya, G,Quax, WJ,de Jong, S,Samali, A,Serrano, L (2012) 'Kinetics in Signal Transduction Pathways Involving Promiscuous Oligomerizing Receptors Can Be Determined by Receptor Specificity: Apoptosis Induction by TRAIL'. Molecular & Cellular Proteomics, 11 . [DOI] [Details]|
|Gupta S, Giricz Z, Natoni A, Donnelly N, Deegan S, Szegezdi E, Samali A (2012) 'NOXA contributes to the sensitivity of PERK-deficient cells to ER stress'. Febs Letters, 586 (22):4023-4030. [DOI] [Details]|
|Mahalingam, Devalingam,N.A.M. Oldenhuis, Corina,Szegezdi, Eva,J. Giles, Francis,G.E. de Vries, Elisabeth,de Jong, Steven,T. Nawrocki, Steffan (2011) 'Targeting Trail Towards the Clinic'. Current Drug Targets, 12 (1414):2079-2090. [Details]|
|van Dijk M, Murphy E, Morrell M , Knapper S , O'Dwyer M, Samali A, Eva Szegezdi E. (2011) 'The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis'. Cancers, 3 :1329-1350. [ARAN Link] [Details]|
|Szegezdi, E,Reis, CR,van der Sloot, AM,Natoni, A,O'Reilly, A,Reeve, J,Cool, RH,O'Dwyer, M,Knapper, S,Serrano, L,Quax, WJ,Samali, A (2011) 'Targeting AML through DR4 with a novel variant of rhTRAIL'. Journal Of Cellular And Molecular Medicine, 15 :2216-2231. [DOI] [Details]|
|Mahalingam, D,Natoni, A,Keane, M,Samali, A,Szegezdi, E (2010) 'Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells'. British Journal Of Cancer, 102 :754-764. [DOI] [Details]|
|Reis, CR,van der Sloot, AM,Natoni, A,Szegezdi, E,Setroikromo, R,Meijer, M,Sjollema, K,Stricher, F,Cool, RH,Samali, A,Serrano, L,Quax, WJ (2010) 'Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants'. Cell Death & Disease, 1 . [DOI] [Details]|
|Gupta, S., Cuffe, L., Szegezdi, E., Logue, S., Neary, C., Healy, S., et al. (2010) 'Mechanisms of ER Stress-Mediated Mitochondrial Membrane Permeabilization'. Int J Cell Biol, 170215 . [ARAN Link] [Details]|
|Vrielink, J,Heins, MS,Setroikromo, R,Szegezdi, E,Mullally, MM,Samali, A,Quax, WJ (2010) 'Synthetic constrained peptide selectively binds and antagonizes death receptor 5'. Febs Journal, 277 :1653-1665. [DOI] [Details]|
|Szegezdi E, Macdonald DC, Ní Chonghaile T, Gupta S, Samali A. (2009) 'Bcl-2 family on guard at the ER'. American Journal Of Physiology: Cell Physiology, . [ARAN Link] [Details]|
|Mahalingam, D,Keane, M,Pirianov, G,Mehmet, H,Samali, A,Szegezdi, E (2009) 'Differential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines'. British Journal Of Cancer, 100 :1415-1424. [DOI] [Details]|
|Reis, CR,van der Sloot, AM,Szegezdi, E,Natoni, A,Tur, V,Cool, RH,Samali, A,Serrano, L,Quax, WJ (2009) 'Enhancement of Antitumor Properties of rhTRAIL by Affinity Increase Toward its Death Receptors'. Biochemistry, 48 :2180-2191. [DOI] [Details]|
|Plantivaux, A.,Szegezdi, E.,Samali, A.,Egan, L. (2009) 'Is There a Role for Nuclear Factor kappa B in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance?'. Annals N.Y. Acad. Sci, 1171 :38-49. [Details]|
|Gupta, S.,Kass, G. E. N.,Szegezdi, E.,Joseph, B. (2009) 'The mitochondrial death pathway: a promising therapeutic target in diseases'. Journal Of Cellular And Molecular Medicine, 13 (66):1004-1033. [Details]|
|Mahalingam, D.,Szegezdi, E.,Keane, M.,de Jong, S.,Samali, A. (2009) 'TRAIL receptor signalling and modulation: Are we on the right TRAIL?'. Cancer Treatment Reviews, 35 (33):280-288. [Details]|
|Szegezdi, E.,Reed Herbert, K.,Kavanagh, E. T.,Samali, A.,Gorman, A. M. (2008) 'Nerve growth factor blocks thapsigargin-induced apoptosis at the level of the mitochondrion viaregulation of Bim'. Journal Of Cellular And Molecular Medicine, 12 (6A6A):2482-2496. [Details]|
|Holohan, C., Szegezdi, E., Ritter, T., O'Brien, T., Samali, A. (2008) 'Cytokine-induced beta-cell apoptosis is NO dependent, mitochondria-mediated and inhibited by bcl-xl'. J. Cell Mol Med, 12 (2):591-606. [DOI] [Details]|
|Tur, V,van der Sloot, AM,Reis, CR,Szegezdi, E,Cool, RH,Samali, A,Serrano, L,Quax, WJ (2008) 'DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design'. Journal Of Biological Chemistry, 283 :20560-20568. [DOI] [Details]|
|Mylotte, LA,Duffy, AM,Murphy, M,O'Brien, T,Samali, A,Barry, F,Szegezdi, E (2008) 'Metabolic flexibility permits mesenchymal stem cell survival in an ischemic environment'. Stem Cells and Development, 26 :1325-1336. [DOI] [Details]|
|Tur V, van der Sloot AM, Reis CR, Szegezdi E, Cool RH, Serrano L Samali A and Quax W (2008) 'Structure based design of a DR4 selective TRAIL variant'. Journal Of Biological Chemistry, 283 :20560-20568. [Details]|
|Kiss, I.,Ruhl, R.,Szegezdi, E.,Fritzsche, B.,Toth, B.,Pongracz, J.,Perlmann, T.,Fesus, L.,Szondy, Z. (2008) 'Retinoid receptor-activating ligands are produced within the mouse thymus during postnatal development'. European Journal of Immunology, 38 (11):147-155. [Details]|
|Samali, A,O'Mahoney, M,Reeve, J,Logue, S,Szegezdi, E,McMahon, J,Fearnhead, HO (2007) 'Identification of an inhibitor of caspase activation from heart extracts; ATP blocks apoptosome formation'. Apoptosis, 12 :465-474. [DOI] [Details]|
|Reeve, JLV,Szegezdi, E,Logue, SE,Chonghaile, TN,O'Brien, T,Ritter, T,Samali, A (2007) 'Distinct mechanisms of cardiomyocyte apoptosis induced by doxorubicin and hypoxia converge on mitochondria and are inhibited by Bcl-X-L'. Journal Of Cellular And Molecular Medicine, 11 :509-520. [DOI] [Details]|
|Ni Chonghaile, T,Concannon, CG,Szegezdi, E,Gorman, AM,Samali, A (2006) 'Dexamethasone inhibits apoptosis in C6 glioma cells through increased expression of Bcl-X-L'. Apoptosis, 11 :1247-1255. [DOI] [Details]|
|Szegezdi, E,Cahill, S,Meyer, M,O'Dwyer, M,Samali, A (2006) 'TRAIL sensitisation by arsenic trioxide is caspase-8 dependent and involves modulation of death receptor components and Akt'. British Journal Of Cancer, 94 :398-406. [DOI] [Details]|
|Szegezdi, E.,Logue, S. E.,Gorman, A. M.,Samali, A. (2006) 'Mediators of endoplasmic reticulum stress-induced apoptosis'. Embo Reports, 7 (99):880-885. [Details]|
|Van der Sloot, AM,Tur, V,Szegezdi, E,Mullally, MM,Cool, RH,Samali, A,Serrano, L,Quax, WJ (2006) 'Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor'. Proceedings Of The National Academy Of Sciences Of The United States Of America, 103 :8634-8639. [DOI] [Details]|
|Szegezdi, E,Duffy, A,O'Mahoney, ME,Logue, SE,Mylotte, LA,O'Brien, T,Samali, A (2006) 'ER stress contributes to ischemia-induced cardiomyocyte apoptosis'. Biochemical And Biophysical Research Communications, 349 :1406-1411. [DOI] [Details]|
|Gorman A.M., Szegezdi E., Quigney D., Samali A. (2005) 'Hsp27 inhibits 6-Hydroxydopamine induces both apoptosis and heat shock response in PC12 cells: role of hsp27 in protection against apoptosis'. Biochemical And Biophysical Research Communications, 327 :801-810. [Details]|
|Concannon, CG,FitzGerald, U,Holmberg, CI,Szegezdi, E,Sistonen, L,Samali, A (2005) 'CD95-mediated alteration in Hsp70 levels is dependent on protein stabilization'. Cell Stress & Chaperones, 10 :59-65. [Details]|
|Gorman A.M., Szegezdi E., Quigney D., Samali A. (2005) '6-Hydroxydopamine induces both apoptosis and heat shock response in PC12 cells: role of hsp27 in protection against apoptosis'. Biochem. Biophys. Res. Commun, 327 :801-810. [Details]|
|Szondy, Z.,Sarang, Z.,Molnar, P.,Nemeth, T.,Piacentini, M.,Mastroberardino, P. G.,Falasca, L.,Aeschlimann, D.,Kovacs, J.,Kiss, I.,Szegezdi, E.,Lakos, G.,Rajnavolgyi, E.,Melino, G.,Fesus, L. (2004) 'TGase2 is required for proper phagocytosis of apoptotic cells and to prevent autoimmunity'. Tissue Antigens, 64 (44):342-343. [Details]|
|Szegezdi, E.,Fitzgerald, U.,Samali, A. (2003) 'Caspase-12 and ER-stress-mediated apoptosis - The story so far'. Annals N.Y. Acad. Sci, 1010 :186-194. [Details]|
|O'Mahoney, M. E.,Logue, S.,Szegezdi, E.,Stenson-Cox, C.,Fitzgerald, U.,Samali, A. (2003) 'Hypoxia and ischemia induce nuclear condensation and caspase activation in cardiomyocytes'. Annals N.Y. Acad. Sci, 1010 :728-732. [Details]|
|Szondy, Z.,Toth, R.,Szegezdi, E.,Reichert, U.,Ancian, P.,Fesus, L. (2001) 'Cell death in HIV pathogenesis and its modulation by retinoids'. Natural Compounds and Their Role in Apoptotic Cell Signaling Pathways, 946 :95-107. [Details]|
|Toth, R.,Szegezdi, E.,Reichert, U.,Bernardon, J. M.,Michel, S.,Ancian, P.,Kis-Toth, K.,Macsari, Z.,Fesus, L.,Szondy, Z. (2001) 'Activation-induced apoptosis and cell surface expression of Fas (CD95) ligand are reciprocally regulated by retinoic acid receptor alpha and gamma and involve nur77 in T cells'. European Journal of Immunology, 31 (55):1382-1391. [Details]|
|Szegezdi, E.,Szondy, Z.,Nagy, L.,Nemes, Z.,Friis, R. R.,Davies, P. J. A.,Fesus, L. (2000) 'Apoptosis-linked in vivo regulation of the tissue transglutaminase gene promoter'. Cell Death and Differentiation, 7 (1212):1225-1233. [Details]|
|O'Reilly, P; O'Connell, E; Gernon, G; Szegezdi, E. (2014) Panel of 25 co-acting genes identified as a powerful predictor of TRAIL sensitivity Irish Association for Cancer Research [Details]|
|Quax, W. J.,Reis, C. R.,van der Sloot, A. M.,Tur, V.,Szegezdi, E.,Natoni, A.,Cool, R. H.,Samali, A.,Serrano, L. (2011) Designed Receptor Specific Rhtrail Variants Enhance Induction of Apoptosis in Cancer Cells Advances in Tnf Family Research , pp.726-727 [Details]|
|Reis, C. R.,van der Sloot, A. M.,Szegezdi, E.,Natoni, A.,Tur, V.,Cool, R. H.,Samali, A.,Serrano, L.,Quax, W. J. (2011) Enhancement of Antitumor Properties of Rhtrail by Affinity Increase toward Its Death Receptors Advances in Tnf Family Research , pp.807-808 [Details]|
|van der Sloot, A. M.,Szegezdi, E.,Reis, C. R.,Tur, V.,Quax, W. J.,Samali, A.,Serrano, L. (2011) Computational Design of Receptor Selective Trail Variants Advances in Tnf Family Research , pp.809-809 [Details]|
|van Dijk, M.,Pronai, I.,Somali, A.,Szegezdi, E. (2011) Trail Resistance in Non-Transformed Cells Is Provided by Multiple Factors Advances in Tnf Family Research , pp.821-821 [Details]|
|Morrell, R. C.,Szegezdi, E.,Halpin-McCormick, A.,Cawley, K.,Samali, A.,O'Dwyer, M. (2010) The BH3 Mimetic, ABT-737, Overcomes Stromal-Mediated Pro-Survival Signals and Synergizes with PHA-767491, a Dual Cdc7/CDK9 Inhibitor, In Acute Myeloid Leukaemia American Society of Hematology Meeting Abstract , pp.768-768 [Details]|
|Mahalingam, D.,Medina, E.,Swords, R. T.,Kelly, K. R.,Carew, J. S.,Robbert, C. H.,Szegezdi, E.,Francis, G. J.,de Jong, S.,Nawrocki, S. T. (2009) Effect of sunitinib on TRAIL-induced apoptosis in preclinical colon cancer models AMER SOC CLINICAL ONCOLOGY Meeting Abstract [Details]|
|Plantivaux, A,Szegezdi, E,Samali, A,Egan, L (2009) NATURAL COMPOUNDS AND THEIR ROLE IN APOPTOTIC CELL SIGNALING PATHWAYS Is There a Role for Nuclear Factor kappa B in Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Resistance? , pp.38-49 [DOI] [Details]|
|Plantivaux A, Szegezdi E, Samali A, Egan LJ. (2008) TRAIL resistance in colon cancer cells: is NF-?B involved? APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS [Details]|
|Szegezdi E, Mahalingam D, Van der Sloot A, Quax W, Keane M, Samali A (2007) Decoy-insensitive TRAIL variants kill tumour cells more efficiently without damaging non-transformed cells Proceedings Of The American Association For Cancer Research. Annual Meeting [Details]|
|SZEGEZDI, E et al. (2003) Caspase-12 and ER-stress-mediated apoptosis - The story so far APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS , pp.186-194 [Details]|
|Cahill, S.,Szegezdi, E.,Samali, A.,O'Dwyer, M. (2003) Arsenic trioxide sensitizes leukemic cells to TRAIL-induced apoptosis American Society of Hematology. Meeting Abstract [Details]|
|O'Mahoney, ME,Logue, S,Szegezdi, E,Stenson-Cox, C,Fitzgerald, U,Samali, A (2003) APOPTOSIS: FROM SIGNALING PATHWAYS TO THERAPEUTIC TOOLS Hypoxia and ischemia induce nuclear condensation and caspase activation in cardiomyocytes , pp.728-732 [DOI] [Details]|
Honours and Awards
| Year: 2015.
Title: Irish Blood Cancer Network
| Year: 2008.
Title: Development of antagonistic cytokine variants for treatment of type I diabetes
| Year: 2013.
Title: Development of Ex Vivo Diagnostic Multivariate Index Assay for Prediction of Treatment Efficacy in Acute Leukemias
| Year: 2009.
Title: Irish Cancer Society research Fellowship - Uncoupling of death receptor-induced nuclear factor kappa B activation from apoptosis.
| Year: 2009.
Title: Starting Investigator Research Grant Award
|Association: Irish Association for Cancer Research, Function/Role: member|
|Association: European Association for Cancer Research, Function/Role: member|
|Association: Biochemical Society, Function/Role: member|
|Patent UK Patent Application No. 0818649.6 : Treatment of proliferative disorders with TRAIL|
|Patent WO2005056596 : Improved cytokine design|
|Eva Szegezdi (2013) Annual international meeting of the Americal Cell death society on cell death signal transduction. [Invited Oral Presentation], Annual Meeting of the International Cell Death Society, Fuengirola, Spain , 06-JUN-13 - 09-JUN-13.|
|Eva Szegezdi (2013) Biannual world meeting on TNF cytokine signalling. [Invited Oral Presentation], 14th International TNF Conference, Quebec, Canada , 07-JUL-13 - 10-JUL-13.|
|Szegezdi, E (2008) An international workshop on apoptosis research. [Invited Lecture], ICAS/ApopTrain International Apoptosis Workshop, Günzburg, Germany , 14-JUN-08 - 16-JUN-08.|
|Gorman A, Szegezdi E, Samali A. (2010) A one day international meeting of researchers in Galway, 2010. [Conference Organising Committee Member], Apoptosis Symposium, Galway , 20-AUG-10 - 20-AUG-10.|
|L O’Leary, A van der Sloot, C Reis, RH Cool, P Correa de Sampaio, G Murphy, WJ Quax, L Serrano, A Samali, E Szegezdi (2012) The first conference on the role of cell death in cancer organised by EACR. [Oral Presentation], European Asociation of Cancer Research - Cell Death and Cancer Special conference, Amsterdam, the Netherlands , 25-JAN-12 - 28-JAN-12.|
| Employer: University of Debrecen, Hungary
Position: Postdoctoral researcher
| Employer: National University of Ireland, Galway
Position: postdoctoral researcher
| Employer: National University of Ireland, Galway
| Year 2000 Institution: University of Debrecen, Hungary
Qualification: PhD Subject: Medical Science
| Year 1996 Institution: University of Debrecen, Hungary
Qualification: Msc Subject: Biochemistry and Molecular Biology
Sara Cahill B.Sc.; H. Dip. Micro; M.Sc., 2002-2006
Ph.D. thesis Title: Mechanisms and of caspase activation in T cell activation
Eoin Murphy, B.Sc., 2006-2008
M.Sc. thesis title: TRAIL and Bortezomib: a dual targeted approach against acute myeloid leukaemia
Louise Mylotte, B.Sc., 2004-2008
Ph.D. thesis title: Mechanism of mesenchymal stem cell-mediated cardiac repair
Deva Mahalingam, MB BCh BAO, MRCP(UK) & MRCP(I), 2005-2009
Ph.D. thesis title: Novel regulators of TRAIL-induced apoptosis
Marianne van Dijk, M.Sc., 2007-2011
Ph.D. project title: Mechanism of TRAIL resistance in non-transformed cells
|2013/14 MD140 : Metabolism and Nutrition|
|2013/14 MD138 : Biomolecules, Metabolism and Energy|